• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Economy OPK Stock Price, Analysis and Forecast: Should You Invest
Economy

OPK Stock Price, Analysis and Forecast: Should You Invest

by September 13, 2024
by September 13, 2024 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

Should You Invest in OPK Stock?

OPKO Health, one of the leading pharmaceutical companies, is a key player in the market. If you’re considering investing in the health and pharmaceutical sector, particularly in OPK stock, keep reading to find out more.

OPKO Health shareholders have experienced a 36% decline over the past year, while the broader market has risen 25%. The stock will find some support from the long-term average at approximately $1.51 on a fall. A break-up through the short-term average will send a buy signal. Let’ see in detail OPK stock price analysis and forecasts. 

OPK Stock Price Today

Opko Health, Inc. (OPK) is a healthcare company trading at $1.59 per share. Over the past 52 weeks, the stock has fluctuated between a low of $0.85 and a high of $1.76. The company has a market capitalisation of $1.1 billion, classifying it as a small-cap stock. Opko Health does not pay any dividends, which might affect income-seeking investors. The stock has a beta of 1.64, indicating it is more volatile than the broader market.

Investors looking to buy OPKO stock should consider its current price stability and market volatility. The stock’s lack of dividends may deter those seeking regular income. However, its relatively low price could attract those seeking growth in the healthcare sector.

Before investing, it is essential to understand the company’s fundamentals and market position. Opko Health operates in a competitive healthcare environment, and its stock performance reflects this.

The company may offer an opportunity for growth-focused investors, but its volatility and lack of dividends should be considered. Researching thoroughly and assessing personal financial goals before deciding to invest is important.

OPK Stock Forecast: New Price Targets

OPK stock news has received various research ratings. Barrington Research increased its price target from $1.50 to $2.25, rating the stock “outperform.” HC Wainwright reissued a “buy” rating with a $3.00 target price. Piper Sandler lowered its target from $5.00 to $3.00 and rated it “overweight.”

OPKO Health has a market cap of $1.12 billion, a negative P/E ratio of -4.57, and a beta of 1.65. Its quarterly earnings beat expectations, reporting a loss of $0.01 per share versus an expected loss of $0.09. Revenue fell 31.3% year over year to $182.20 million. Analysts predict OPKO will post a -0.29 EPS for the year.

Insider Activity at OPKO Health

OPKO Health’s major shareholder sold 12,994 shares on August 6th at $29.35 per share, totalling $381,373.90. After the sale, the shareholder holds 2,971,570 shares, valued at $87,215,579.50. Over the last 90 days, insiders sold 736,644 shares worth $23,874,134. Insiders currently own 47.26% of the company’s stock.

Recent insider sales at OPKO Health indicate potential caution among major shareholders despite their significant remaining ownership stake.

OPKO Health: Different Segments

The company has multiple branches that research and deal with different fields. For example, the Diagnostics segment includes BioReference Laboratories, leading clinical laboratories offering comprehensive healthcare testing solutions. Meanwhile, the Pharmaceuticals segment encompasses speciality pharmaceuticals, such as Rayaldee, used to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease, and VARUBI, which addresses chemotherapy-induced nausea and vomiting. In addition, OPKO Health is developing a potential cure for type 1 diabetes and enhancing patient outcomes through strategic partnerships and innovative solutions.

Final Thoughts: OPK Stock, Buy or Sell?

The OPKO Health stock provides both opportunities and risks for investors. Its current low price and long-term potential in the healthcare and pharmaceutical sectors may attract growth-focused investors, particularly given the company’s work on innovative treatments like a potential cure for type 1 diabetes. However, the stock’s volatility, lack of dividends, and recent insider sales suggest caution. Investors should consider their risk tolerance and long-term goals before investing in OPKO Health.

The post OPK Stock Price, Analysis and Forecast: Should You Invest appeared first on FinanceBrokerage.

You Might Also Like
  • Hunter Biden went from ‘sweetheart deal’ to ‘poison pill:’ legal experts break down derailed plea deal
  • In New Hampshire, abortion activists score win as proposed restrictions fail in state House
  • AOC slammed for saying ‘false accusations’ of antisemitism are ‘wielded against people of color’
  • CA Senate passes bill to redefine same-sex couples unable to get pregnant as ‘infertile’
Share
0
FacebookTwitterPinterestWhatsapp

previous post
SafeMoon and Litecoin: SafeMoon is holding above the EMA 200
next post
Dogecoin and Shiba Inu: Doge continues on the positive side

You may also like

Hunter Biden’s daughter with ex-stripper will receive some of his...

June 30, 2023

Biden admin clears major West Virginia gas pipeline after weeks...

May 16, 2023

Payroll Gains Beat Expectations, but the Pace Is Slowing

December 2, 2022

Biden not in contact with Dem leaders on the Hill,...

July 2, 2024

New York City becomes first government to distribute free abortion...

January 19, 2023

Trump-backed GOP congresswoman survives challenge from right in deep-red New...

June 26, 2024

Schumer pledges ‘supercharged’ path to AI regulation when Senate returns...

September 4, 2023

Chris Christie fumes over Trump’s ‘absurd’ claims on indictment: ‘Three...

June 26, 2023

Aggregate Demand and Aggregate Supply: Keep It Simple, Stupid!

November 28, 2022

Trump-backed Majewski launches 2nd bid against longtime Ohio House Democrat...

April 13, 2023

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • OpenAI to release web browser in challenge to Google Chrome

      July 10, 2025
    • Sports executive charged with bid-rigging in Texas arena project

      July 10, 2025
    • How I Triple My Returns With 3x Leveraged ETFs!

      July 10, 2025
    • Want Faster, Lower Risk Trades? Use This Setup

      July 9, 2025
    • The Seasonality Trend Driving XLK and XLI to New Highs

      July 9, 2025

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 3,631 views
    • 2

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,919 views
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,607 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,577 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,449 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,169)
    • Investing (538)
    • Stock (2,661)

    Popular Posts

    • 1

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 2

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 3

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • OpenAI to release web browser in challenge to Google Chrome

      July 10, 2025
    • Sports executive charged with bid-rigging in Texas arena project

      July 10, 2025
    • How I Triple My Returns With 3x Leveraged ETFs!

      July 10, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,169)
    • Investing (538)
    • Stock (2,661)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    Ex-Gov. Andrew Cuomo faces new lawsuit...

    April 9, 2023

    Super Tuesday countdown: Haley notches her...

    March 4, 2024

    Mayorkas pleads with migrants not to...

    May 6, 2023
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here